A recently completed elderly study of the European MCL (mantle cell lymphoma) network demonstrates the efficacy of "rituximab (R) - maintenance...in MRD (minimal residual disease) patients after R-CHOP induction [resulting in] substantially prolonged progression-free survival and overall survival." Study authors also supported the need to advocate for MRD efficacy, thereby "establishing novel risk-adapted treatment strategies."
To read more about this study, click here.
Source mentioned: Hoster E, Delfau-Larue M-H, Macintyre E, et al. on behalf of the European MCL MRD Working Group and the European MCL Network. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial. JCO; Published online 22 November 2023. DOI: 10.1200/JCO.23.00899
No comments:
Post a Comment